美国 · SEC FORM 4
NovoCure Ltd
NVCR · Nasdaq · CIK 0001645113 · Healthcare · Medical Devices
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
21 同一窗口内观察到的 Form 4 交易行
8 sales · 13 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 6 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-09-05 · Cordova Ashley.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 11,163,094
- 上期报告
- 11,796,425
- 日均成交量
- 1,110,466
- 回补天数
- 10.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-09-05 | Cordova Ashley | 买入 (P) | Ordinary Shares | 81,550 | USD 12.22 | USD 996,541 | SEC 申报 ↗ |
| 2025-07-29 | Brackmann Christoph | 买入 (P) | Ordinary Shares | 20,000 | USD 11.59 | USD 231,800 | SEC 申报 ↗ |
| 2021-11-26 | Danziger Asaf | 买入 (P) | Ordinary Shares | 4,974 | USD 102.44 | USD 509,539 | SEC 申报 ↗ |
| 2020-09-02 | Shah Pritesh | 买入 (P) | Ordinary Shares | 4,200 | USD 85.01 | USD 357,042 | SEC 申报 ↗ |
Form 4 申报证据
63 transaction lines in the latest 365-day window; 773 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Puri Michal Nath | 奖励/授予 (A) | Ordinary Shares | 1,905 | USD 11.15 | USD 21,241 | SEC 申报 ↗ |
| 2026-06-30 | Leonard Frank X | 奖励/授予 (A) | Ordinary Shares | 1,905 | USD 11.15 | USD 21,241 | SEC 申报 ↗ |
| 2026-06-30 | Danziger Asaf | 奖励/授予 (A) | Ordinary Shares | 268 | USD 11.15 | USD 2,988 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Puri Michal Nath | 奖励/授予 (A) | Ordinary Shares | 1,905 | USD 11.15 | USD 21,241 | SEC 申报 ↗ |
| 2026-06-30 | Leonard Frank X | 奖励/授予 (A) | Ordinary Shares | 1,905 | USD 11.15 | USD 21,241 | SEC 申报 ↗ |
| 2026-06-30 | Danziger Asaf | 奖励/授予 (A) | Ordinary Shares | 268 | USD 11.15 | USD 2,988 | SEC 申报 ↗ |
| 2026-06-30 | Ben Arye Barak | 奖励/授予 (A) | Ordinary Shares | 1,299 | USD 11.15 | USD 14,484 | SEC 申报 ↗ |
| 2026-06-04 | Leonard Frank X | 卖出 (S) | Ordinary Shares | 34,273 | USD 17.93 | USD 614,515 | SEC 申报 ↗ |
| 2026-06-03 | VERNON W ANTHONY | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Stafford Kristin | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Scannell Timothy J | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Ocean Allyson J | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Madden Martin J. | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | LEUNG GABRIEL | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | Hung David | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-03 | HILLEMAN JERYL L | 奖励/授予 (A) | Ordinary Shares | 11,610 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-02 | VERNON W ANTHONY | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | Stafford Kristin | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | Scannell Timothy J | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | Ocean Allyson J | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | LEUNG GABRIEL | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | Hung David | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-06-02 | HILLEMAN JERYL L | 卖出 (S) | Ordinary Shares | 2,945 | USD 15.77 | USD 46,443 | SEC 申报 ↗ |
| 2026-04-28 | VERNON W ANTHONY | 期权行权/转换 (M) | Ordinary Shares | 21,500 | USD 11.39 | USD 244,885 | SEC 申报 ↗ |
| 2026-03-05 | Paravasthu Mukund | 卖出 (S) | Ordinary Shares | 43,246 | USD 13.77 | USD 595,497 | SEC 申报 ↗ |
| 2026-03-04 | Weinberg Uri | 卖出 (S) | Ordinary Shares | 6,412 | USD 13.31 | USD 85,344 | SEC 申报 ↗ |
| 2026-03-04 | Puri Michal Nath | 卖出 (S) | Ordinary Shares | 1,100 | USD 13.31 | USD 14,641 | SEC 申报 ↗ |
| 2026-03-04 | Paravasthu Mukund | 卖出 (S) | Ordinary Shares | 5,377 | USD 13.31 | USD 71,568 | SEC 申报 ↗ |
| 2026-03-04 | Leupin Nicolas | 卖出 (S) | Ordinary Shares | 1,100 | USD 13.31 | USD 14,641 | SEC 申报 ↗ |
| 2026-03-04 | Leonard Frank X | 卖出 (S) | Ordinary Shares | 5,607 | USD 13.31 | USD 74,629 | SEC 申报 ↗ |
| 2026-03-04 | Cordova Ashley | 代扣税 (F) | Ordinary Shares | 17,638 | USD 13.30 | USD 234,585 | SEC 申报 ↗ |
| 2026-03-04 | Brackmann Christoph | 卖出 (S) | Ordinary Shares | 6,412 | USD 13.31 | USD 85,344 | SEC 申报 ↗ |
| 2026-03-03 | Weinberg Uri | 奖励/授予 (A) | Ordinary Shares | 50,125 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NVCR |
| CIK | 0001645113 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 773 transaction lines from 2020-01-08 to 2026-06-30 8 P purchase lines · 457 S sale lines · 308 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.